Abstract
The immune system recognizes and potentially eliminates tumors that express antigenic molecules. The theory of “cancer immunosurveillance”, describing lymphocytes as sentinels capable of recognizing nascent transformed cells and thus maintaining tissue homeostasis, has been proposed as far back as 50 years ago. The modern vision of immune responses against cancer is more complex because the immune system sculpts the immunogenic phenotype of developing tumors by not only facilitating their elimination, but also their progression in regards to the role of regulatory T cells and the subpopulation of natural killer T cells (NKT). Manipulation of adaptive immunity through therapeutic approaches is relevant to prevent metastasis and, in some cases, to treat primary tumors if the relevant antigens have been identified. Here we review the use of glycoconjugates containing tumor-associated carbohydrate antigens (TACA) in immunotherapy and their use as vaccines in clinical and pre-clinical trials. We also describe a new experimental vaccine model for the generation of CD8+ cytotoxic T cells (CTL) that involves designer TACA-containing glycopeptides with high affinity for class I molecules of the major histocompatibility complex (MHC).
Keywords: Tumor Associated Carbohydrate Antigens, adaptive immunity, cytotoxic T cells
Anti-Cancer Agents in Medicinal Chemistry
Title: Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Volume: 8 Issue: 1
Author(s): Alssandra Franco
Affiliation:
Keywords: Tumor Associated Carbohydrate Antigens, adaptive immunity, cytotoxic T cells
Abstract: The immune system recognizes and potentially eliminates tumors that express antigenic molecules. The theory of “cancer immunosurveillance”, describing lymphocytes as sentinels capable of recognizing nascent transformed cells and thus maintaining tissue homeostasis, has been proposed as far back as 50 years ago. The modern vision of immune responses against cancer is more complex because the immune system sculpts the immunogenic phenotype of developing tumors by not only facilitating their elimination, but also their progression in regards to the role of regulatory T cells and the subpopulation of natural killer T cells (NKT). Manipulation of adaptive immunity through therapeutic approaches is relevant to prevent metastasis and, in some cases, to treat primary tumors if the relevant antigens have been identified. Here we review the use of glycoconjugates containing tumor-associated carbohydrate antigens (TACA) in immunotherapy and their use as vaccines in clinical and pre-clinical trials. We also describe a new experimental vaccine model for the generation of CD8+ cytotoxic T cells (CTL) that involves designer TACA-containing glycopeptides with high affinity for class I molecules of the major histocompatibility complex (MHC).
Export Options
About this article
Cite this article as:
Franco Alssandra, Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/187152008783330888
DOI https://dx.doi.org/10.2174/187152008783330888 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuronal Membranes are Key to the Pathogenesis of Alzheimers Disease: the Role of Both Raft and Non-Raft Membrane Domains
Current Alzheimer Research Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Synthesis and Biological Activity of Unnatural Enediynes
Current Medicinal Chemistry The Proline-Rich Domain and the Microtubule Binding Domain of Protein Tau Acting as RNA Binding Domains
Protein & Peptide Letters Cell-Selective Mitochondrial Targeting: Progress in Mitochondrial Medicine
Current Drug Delivery Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review
Current Medicinal Chemistry NPFF2 Receptor is Involved in the Modulatory Effects of Neuropeptide FF for Macrophage Cell Line
Protein & Peptide Letters Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections
Current Medicinal Chemistry Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry